Tumor suppression by Tegafur combined with Barbadian in S‑180 tumor‑bearing mice

: The aim of this study was to discuss the antitumor effect of Tegafur combined with Barbadian on S-180 tumor-bearing mice. A murine tumor model was prepared by subcutaneous injection of S-180 sarcoma cells to the armpit of the right limb of healthy female SPF KM mice. The 24 tumor-bearing mice were randomly divided into 4 groups: Combination therapy group of Tegafur and Barbadian, Barbadian group, Tegafur group and normal saline control group. Corresponding test substances were given to each group by intragastric administration, respectively, 0.2 ml/mouse, once/day, continuous 5 days, interval for 2 days, recorded as 1 period, 3 periods were continuously performed. Antitumor rate, immune cells, blood biochemistry and inflammatory mediators and other indexes were then respectively measured. Result showed that the antitumor rate for the Combination group was 78%; Barbadian group, 72%; and Tegafur group, -89%. White blood cells (WBC) in Barbadian group was significantly higher than that in the control group (P<0.01); lymphocytes (LYMPH), Barbadian group was significantly higher than that in the control group (P<0.01), Tegafur group was significantly lower than the control group (P<0.01); monocytes (MONO), all drug groups were significantly higher than the control group (P<0.01); neutrophils (NEUT), combination group (P<0.01) and Barbadian group (P<0.05) were significantly higher than the control group; blood sugar for the combination (P<0.05) and Barbadian (P<0.01) groups were significantly higher than the control group, while the Tegafur group was significantly lower than the control group (P<0.01). Cholesterol and BUN in the Tegafur group were significantly higher than that in control group (P<0.05). For IL-1, the combination and Barbadian groups were significantly higher than the control group (P<0.05), while for IL-6, all the drug groups were significantly higher than the control group (P<0.05). TNF-α in the Tegafur group was significantly lower than that in the control group (P<0.05). In conclusion, the combination of Tegafur and Barbadian has the significant effect of inhibiting mice S-180 sarcoma. The single use of chemotherapeutic drug Tegafur has no significant inhibitory effect on mice S-180 sarcoma. The single use of Barbadian has good antitumor effect and can resist the significant decrease of lymphocytes caused by the chemotherapeutic drug Tegafur. Thus, Barbadian has a good antitumor effect and can protect the immune system of the body, making it a viable treatment option.